Lok A, Mocquard J, Bourcier J, Redelsperger L, Bonnet A, Chauvin C, Thomaré P, Mahé B, Touzeau C, Moreau P. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica 2014; 99(3):e33-e34; https://doi.org/10.3324/haematol.2013.100396.